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ABSTRACT
Background: This study examines the joint effect on cognition of selective serotonin re-uptake inhibitors
(SSRIs) and cholinesterase inhibitors (AChEIs) in depressed patients affected by Alzheimer’s disease (AD)
living at home.
Methods: The study was conducted in two different outpatient neurological clinics. 338 patients with probable
AD were treated with ChEis (donepezil, rivastigmine and galantamine) as per the clinician’s judgment and were
observed for nine months. At study entry, participants underwent a multidimensional assessment evaluating
cognitive, functional and psychobehavioral domains. All patients were evaluated at baseline, after one (T1),
three (T2) and nine months (T3). Patients were grouped in three different categories (patients not depressed
and not treated with SSRIs, patients depressed and treated with SSRIs, and patients depressed but not treated
with SSRIs).
Results: At baseline 182 were diagnosed as not depressed and not treated with SSRIs, 66 as depressed and
treated with SSRIs, and 90 as depressed but not treated with SSRIs. The mean change in MMSE score
from baseline to nine months showed that depressed patients not treated worsened in comparison with those
not depressed and not treated with SSRIs (mean change −0.8 ± 2.3 vs 0.04 ± 2.9; p = 0.02) and patients
depressed and treated with SSRI (mean change −0.8 ± 2.3 vs 0.1 ± 2.5; p = 0.03).
Conclusions: In AD patients treated with AChEIs, SSRIs may exert some degree of protection against the
negative effects of depression on cognition.
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Introduction
Alzheimer’s disease (AD) is a common disorder
whose psychosocial impact increases as the
proportion of elderly people in the population grows
(Suh and Shah., 2001). To date, the most successful
therapeutic approaches have involved cholinesterase
inhibitors (AChEIs) (Bellelli et al., 2005; Rozzini
et al., 2005).
In elderly subjects depression is a prevalent and
serious disorder that is associated with reduced
quality of life and increased morbidity and mortality
(Blazer et al., 1987). In elderly subjects and in
elderly patients with medical illness or in residential
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settings the prevalence of depression ranges from
7% to 42% (Bruce et al., 1994). Several placebo-
controlled studies on selective serotonin re-uptake
inhibitors (SSRIs) have demonstrated their efficacy
in improving symptoms of depression (Rapaport
et al., 2003).
Since approximately 25–40% of AD patients may
develop depressive symptoms and since a growing
body of research has found cognitive impairment to
be a common clinical feature of late life depression
(Niederehe et al., 1995), our aim is to investigate
pharmacological strategies to improve and stabilize
cognitive functioning in late-life depression and
minimize progression of cognitive impairment. To
this end we evaluated the role on cognition of
combining selective SSRIs with medications used
in AD (donepezil, rivastigmine and galantamine),
hypothesizing a joint effect that may delay cognitive
deterioration.
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Methods
Three hundred and sixty-eight Alzheimer patients
were enrolled consecutively in two different
outpatient clinics (Alzheimer Evaluation Units,
UVA, Brescia, Northern Italy) between January
2003 and January 2006. All patients with
AD met the National Institute of Neurological
and Communicative Disorders and Stroke –
Alzheimer’s Disease and Related Disorders
(NINCDS-ADRDA) criteria for probable AD
(McKhann et al., 1984), as judged by an
experienced AD research clinician. Diagnostic
evaluation included: demographic and clinical
features, medical history, physical and neurological
examination, neuropsychological testing, routine
blood tests (including thyroid hormones, vitamin
B12 level, and serological tests for syphilis),
and neuroimaging with brain computerized
tomography. Duration of the disease was considered
at the time of onset of memory disturbances that
exceeded the episodic forgetfulness that might have
been regarded as usual for the patient, or of other
disturbances (language, praxis, orientation, visuo-
spatial skills) that were clearly related to the disease.
At baseline, participants were assessed by a
neuropsychologist using the Mini-mental State
Examination (MMSE; Folstein et al., 1975), the
Alzheimer’s Disease Assessment Scale ADAS-Cog
(Fioravanti et al., 1994) and the global Clinical
Dementia Rating (CDR; Hughes et al., 1982)
to evaluate the global cognitive function; the
Instrumental Activities of Daily Living (IADL;
Lawton and Brody, 1969) and Basic Activities of
Daily Living (BADL; Katz et al., 1970) to detect
impairment in activity functions; the Geriatric
Depression Scale (GDS) 15 items (Sheikh and
Yesavage, 1986) to study the presence of depressive
symptoms, and the Neuropsychiatry Inventory
(NPI; Cummings et al., 1994), to study psycho-
behavioral disturbances. Every concomitant illness
and treatment was recorded.
Patients were classified as depressed through
clinical and neuropsychiatric investigation with
DSM-IV criteria for depression in Alzheimer’s
disease (American Psychiatric Association, 1994).
All subjects and their caregivers were asked, by
the clinic doctor, about the symptoms of depressed
mood, decrease of interest or pleasure, changes in
appetite, changes in sleep, loss of energy, feelings
of guilt, worthlessness or that life was not worth
living, difficulty in concentrating, and psychomotor
agitation or retardation.
From 368 patients recruited, 30 patients were
excluded from the analysis during the period of
observation: 11 for low compliance (the patients
changed to another clinic or they did not want
to make the periodic visits), nine for nausea
or headache, four for seizures and six patients
for institutionalization. No statistical differences
on demographic, clinical and neuropsychological
characteristics have been observed among the two
groups (analyzed vs excluded).
At the start of the study, patients received
donepezil (n = 227; 67%), rivastigmine (n = 69;
20%) and galantamine (n = 42; 13%) as per
the clinician’s judgment; patients took donepezil
5 mg per day, rivastigmine 1.5 mg/bid per day
and galantamine 4 mg/bid per day. The effects
of treatment were investigated at 1 (T1), 3 (T2)
and 9 (T3) months. At each clinical visit the
dose of AChEIs was increased according to the
investigator’s judgment. If the increased dose was
not tolerated, it was decreased to the previous well-
tolerated dose. All changes were recorded. Patients
were allowed to attend the clinic for any problem
or adverse effect. At three months the mean dose
was 7.5 mg ± 2.5 of donepezil, 6.7 ± 2.1 mg of
rivastigmine and 11.8 ± 4.4 mg of galantamine.
To evaluate the role on cognition of combining
SSRIs with AChEIs we grouped three different
categories of patients: patients not depressed
and not treated with SSRIs at baseline, patients
depressed and treated with SSRIs at baseline, and
patients depressed but not treated with SSRIs. In
our sample there were no patients treated with SSRI
but not depressed. All patients already taking SSRIs
at baseline did not discontinue the therapy during
the period of observation (nine months).
Although the consensus for treatment of AD
patients addresses the importance of additionally
treating behavioral symptoms, the lack of clear
guidelines indicating when and how to treat
depressive symptoms has led us to decide the
prescription of antidepressants in accordance with
a clinical global judgment.
The study was approved by institutional review
boards and written informed consent was obtained
from both the patients and their responsible
caregivers.
Statistical analysis
Statistical analysis was performed with the Statist-
ical Package for the Social Sciences (SPSS, 2002).
Descriptive statistics at baseline were performed on
socio-demographic, clinical, neuropsychological,
functional and psycho-behavioral characterist-
ics. Quantitative variables were expressed as
mean ± standard deviation. Continuous variables
were assessed using analysis of variance (ANOVA)
models and the χ2 test for dichotomous ones. Post-
hoc comparisons, adjusted using the Bonferroni
correction, were used to make comparisons between
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Table 1. Sociodemographic and clinical characteristics of Alzheimer’s patients at baseline treated with
cholinesterase inhibitors and divided in three groups on the basis of depression and SSRI treatment
NOT DEPRESSED
NOT T REAT ED
W I T H S S R I
DEPRESSED
T R E AT E D W I T H
SSRI
DEPRESSED NOT
T R E AT E D W I T H
SSRI
N = 182 N = 66 N = 90
MEAN SD % MEAN SD % MEAN SD %
......................................................................................................................................................................................................................................................................................................................
Age (years) 76,7 6,7 75,7 7,6 75,9 7,2
Sex (female) 63 81 71
Education (years) 5,9 3,1 5,5 2,3 5,7 2,8
Duration of the symptoms (months) 25,1 13,5 23,5 12,7 26,5 13,2
CDR 0,9 0,4 0,8 0,4 0,8 0,3
MMSE 20,3 4,4 20,1 4,3 20,1 4,6
IADL (functions maintained) 4,4 2,3 4,7 2,2 4,4 2,3
ADL (functions maintained) 5,2 1,3 5,3 1,1 5,0 1,4
ADAS Cog 17,8 8,8 16,4 9,3 17,5 10,9
NPI total 12,9∗◦ 11,4 21,7∗ 14,2 21,6◦ 15,5
MMSE mean change GDS 2,1◦ 1,4 8,1◦∗ 2,8 7,3◦∗ 2,3
Number of drugs 0,2◦ 0,4 1,6◦∗ 0,6 0,4∗ 0,6
◦∗p < 0.05 values are based on ANOVA model with post hoc comparisons, adjusted using the Bonferroni correction.
MMSE: Mini-mental State Examination (0–30); ADAS Cog: Alzheimer Disease Assessment Scale, cognitive part (0–70); IADL:
Instrumental Activities Daily Living (0–8); BADL: Basic Activities of Daily Living (0–6); CDR: Clinical Dementia Rating Scale (0–5);
NPI: Neuropsychiatry Inventory (0–144); GDS: Geriatric Depression Scale (0–15); ApoE: Apolipoprotein E
group means at baseline. The significance of change
in three groups (patients not depressed and not
treated with SSRIs at baseline, patients depressed
and treated with SSRIs at baseline, and patients
depressed but not treated with SSRIs) from baseline
to 3 and 9 months for MMSE was evaluated
through General Linear Model repeated measures
(GLM). All tests were 2-tailed at a probability level
of 0.05.
Potential confounders (age, sex, education and
the total GDS score) were evaluated by entering
their values as covariates.
Results
A total of 338 patients with mild to moderate
Alzheimer’s disease were evaluated for nine months.
At baseline, 182 of these were diagnosed as not
depressed and not treated with SSRI, 90 were
classified as depressed and not treated with SSRI
and 66 patients were depressed and treated with
SSRI. Of the last group, 38 reported use of
citalopram (from 10 to 20 mg per day), 15 of
escitalopram (from 5 to 10 mg per day), 10 of
setraline (50 mg per day), two of fluoxetine (20
mg per day) and one of paroxetine (20 mg per
day). As summarized in Table 1, there were no
statistically significant baseline differences between
the three groups in terms of sociodemographic
characteristics. As expected, not treated and treated
(probably not sufficiently because treated by a
family doctor not specialist) depressed patients had
significantly higher mean NPI and GDS scores and
the group of depressed patients treated with SSRIs
took a significantly higher number of drugs than the
other two groups.
At three months (Figure 1), a cognitive
improvement was observed from baseline in non
depressed patients not treated with SSRIs (T2
mean MMSE 20.9 ± 5.2 vs baseline 20.3 ± 4.4;
p = 0.005), in depressed patients treated with
SSRIs (T2 mean MMSE 20.8 ± 5.3 vs baseline
20.1 ± 4.3; p = 0.005) and a cognitive stabilization
in depressed patients not treated with SSRIs (T2
mean MMSE 20.7 ± 5.3 vs baseline 20.6 ± 4.6; p =
NS). At nine months, cognitive stabilization from
baseline characterized non depressed patients not
treated with SSRI (T3 mean MMSE 20.4 ± 5.0
vs baseline 20.3 ± 4.4) and depressed patients
treated with SSRI (T3 mean MMSE 20.2 ± 5.1
vs baseline 20.1 ± 4.3). In contrast, a cognitive
worsening from baseline was observed in depressed
patients not treated with SSRIs (T3 mean MMSE
19.8 ± 5.0 vs baseline 20.6 ± 4.6). Finally, the mean
change in MMSE score from baseline to nine
months demonstrated that depressed patients not
treated worsened when compared with patients
not depressed and not treated with SSRIs and
with patients depressed and treated with SSRIs
(mean change −0.8 ± 2.3 vs 0.04 ± 2.9 vs 0.1 ± 2.5;
p<0.05 respectively).
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Figure 1. Mean change of MMSE after 1, 3 and 9 months of treatment with cholinesterase inhibitors and divided in three groups on the
basis of depression and SSRI treatment at baseline.
The signiﬁcance of change in three groups from baseline to 1, 3, 9 months for MMSE was evaluated using the General Linear Model (GLM).
∗Mean change of MMSE in depressed patients not treated with SSRI versus other two different groups; p≤ 0.05.
Discussion
We observed that use of SSRI medications in people
with AD treated with AChEIs may exert some
degree of protection against the negative effect of
depression on cognition.
A growing body of research has found cognitive
impairment to be a common clinical feature of
late life depression (Niederehe et al., 1995). The
cognitive impairment appears to be associated
with alterations in serotonergic neurotransmission
implicated both directly and through interaction
with central cholinergic pathways (Kalayam and
Alexopoulos, 1999).
Several findings have suggested that SSRIs may
improve different aspects of cognition. Rocca and
colleagues (2005) suggest that citalopram may
improve cognitive disturbances induced by minor
depressive disorder and subsyndromal depressive
symptomatology in elderly patients. Other authors
demonstrate that low dose citalopram is useful
for the treatment of memory deficits and that
acute administration of this drug, through the
augmentation of serotonergic neurotransmission,
facilitates memory consolidation and enhances
long-term memory performance (Harmer et al.,
2002). Escitalopram also has been demonstrated
to improve cognitive efficiency in complex
attention, short- and long-term recall of contextual
information, and short-term recall of visual
information (Savaskan et al., 2007). Improvement
of cognition with SSRIs was also obtained utilizing
sertraline (Constant et al., 2005), fluoxetine
(Levkovitz et al., 2002) and paroxetine (Cassano
et al., 2002).
To date, literature analysis does not clarify if the
combined effect of SSRIs and AChEIs is synergic
or independent (Pelton et al., 2007).
We hypothesize the presence of two potential
mechanisms by which antidepressants affect
cognition in depression: (i) a direct effect caused by
the pharmacologic action of the drugs on specific
neurotransmitters, and (ii) a secondary effect
caused by improvement of depression. The first
hypothesis is sustained by studies demonstrating
that SSRIs change the intracellular iron distribution
that would be predicted to limit indirectly amyloid
precursor protein (APP) expression (e.g. Morse et
al., 2004) and amyloid beta peptide secretion that
are involved in the pathogenesis of AD.
In this regard, Pa´ka´ski and colleagues (2005) in-
dicate that SSRIs are able to interfere with the APP
metabolism in vitro and assert that antidepressant
medication might be beneficial in AD therapy. The
second hypothesis is supported by Vythilingam
and colleagues (2004) who demonstrated that
treatment with antidepressants significantly
improved memory and depression, independently
of detectable brain structural changes.
In a recent pilot study, Pelton and colleagues
(2008) proposed that since serotonin deficits are
known to be associated with depression that
modulates cognitive performance and since the
beneficial effects of cholinesterase inhibitors suggest
that cholinergic neurotransmitter deficits contribute
to the cognitive impairment in AD, the cognitive
improvements by combining antidepressants and
donepezil may involve independent neurotransmit-
ter systems.
A limitation of this observational study includes
the duration of treatment with SSRIs before the
baseline; because the SSRI was administered by the
family doctor we know the initiation of treatment
only in a small group of patients. Another limitation
relates to the decision not to treat with SSRIs
a number of patients with depressive symptoms.
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The decision is supported by data demonstrating
the possible effect of AChEIs on these symptoms
(Rozzini et al., 2007). This option was adopted with
the consent of the caregivers in order to reduce the
number of drugs prescribed to their relatives.
The results support the clinical experience that
treatment of depression with SSRIs in AD patients
who are already on AChEIs might have a slightly
better outcome in cognitive measures.
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